Prostatype Genomics AB (PROGEN) AI Stock Analysis

• Market Cap: kr114.53M
• Dividend Yield: N/A
• Average Volume (3M): 300.11K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.02
• Revenue Growth: -67.76%
• EPS Growth: 95.76%
• Country: SE
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 59,189,320
• 10 Day Avg. Volume: 460,844
• 30 Day Avg. Volume: 300,114
• PEG Ratio: -0.06
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 167.53
• P/FCF Ratio: -0.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -2.7
• Revenue Forecast (FY): kr5.07M

• Rating: 48 Neutral
• Price Target: kr2.00 ▲(166.67% Upside)

Overall score is pressured primarily by weak financial performance (ongoing losses and negative free cash flow with financing reliance). Technicals are supportive with strong momentum and price above major moving averages, but overbought signals temper the outlook. Valuation remains constrained by negative earnings and no dividend data.

Positive Factors

Niche precision diagnostics offering

Prostatype's focus on a prostate‑cancer prognostic test that integrates biomarkers and clinical data creates a specialized clinical utility. That specialization supports durable demand within care pathways, higher switching costs versus general tests, and clearer commercialization focus.

Conservative capital structure (no reported debt)

A healthy equity ratio and lack of reported debt reduce fixed financing burdens and insolvency risk for a small diagnostics firm. This balance sheet position preserves flexibility to raise equity or pursue partnerships without immediate interest costs, aiding multi‑month resilience.

Asset‑light, partnership driven revenue model

Per‑test revenue and commercialization via lab/partner channels, combined with a very small employee base (6), imply an asset‑light cost structure. This supports scalable volume growth with limited fixed overhead, improving the path to durable margin expansion if adoption increases.

Negative Factors

Sustained operating losses

Ongoing negative net income and EBIT show the business has not reached operational profitability. Persistent losses erode equity, limit reinvestment capacity, and imply the company must materially improve margins or revenue to achieve long‑term financial sustainability.

Persistent negative free cash flow

Repeat negative free cash flow and dependence on financing reduce strategic flexibility and increase dilution or refinancing risk. Limited internally generated cash constrains sustained commercialization investments, R&D, and hiring required for durable growth over coming months.

Weak and declining revenue growth

Highly inconsistent and recently steeply negative revenue growth indicates commercialization or market adoption challenges. Without a stabilizing top‑line, margins and cash generation will remain pressured, hampering the company's ability to scale and invest in competitive advantages.

Prostatype Genomics AB Business Overview & Revenue Model

Company Description

Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development of genomic tests aimed at improving the diagnosis and treatment of prostate cancer. The company operates in the healthcare sector, focusing on precision medicine by providing innovative genomic solutions that help clinicians make informed decisions regarding patient management and personalized treatment plans. PROGEN's core product is its proprietary genomic test, which analyzes tumor characteristics to predict disease progression and guide therapeutic choices for prostate cancer patients.

How the Company Makes Money

Prostatype Genomics AB generates revenue primarily through the sale of its genomic testing services to healthcare providers and institutions. The company may charge fees for each test conducted, which can vary based on the complexity and comprehensiveness of the analysis. Additionally, PROGEN could engage in partnerships with pharmaceutical companies and research institutions for collaborative studies or clinical trials, providing further revenue opportunities through grants, licensing agreements, or shared profits from joint ventures. The growing demand for personalized medicine and advancements in genomic technologies also position PROGEN to capitalize on expanding markets and increased adoption of its services.

Prostatype Genomics AB Financial Statement Overview

Summary

Weak fundamentals driven by sustained operating losses (negative net income and EBIT), inconsistent and recently declining revenue trends, and persistent negative free cash flow. The balance sheet shows a comparatively healthy equity ratio and no reported debt, but negative ROE and reliance on financing to fund cash needs remain key risks.

Income Statement

Prostatype Genomics AB has consistently experienced negative net income and negative EBIT over the years, indicating ongoing operational losses. The gross profit margins are not sustainable as they are driven by minimal revenue and high costs. The revenue growth is highly inconsistent, with recent declines suggesting challenges in expanding its market presence.

Balance Sheet

The company maintains a healthy equity ratio, suggesting a strong equity position relative to total assets. However, the absence of total debt in recent reports reflects a lack of leverage, which could indicate limited access to external financing or a conservative financial strategy. The return on equity is negative due to ongoing losses, highlighting inefficiencies in generating returns from shareholders' equity.

Cash Flow

Prostatype Genomics AB's cash flow situation is concerning, with consistent negative free cash flow, indicating that the company is not generating enough cash from operations to fund its capital expenditures. The high operating cash outflow compared to net income suggests operational inefficiencies. The company relies heavily on financing cash flow to meet its cash needs, which could pose sustainability risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	716.00K	199.00K	1.36M	683.00K	10.00K	683.88K
Gross Profit	-11.24M	1.92M	3.73M	683.00K	2.51M	-14.20M
EBITDA	-41.42M	-37.40M	-38.02M	-26.79M	-15.46M	-15.76M
Net Income	-45.31M	-41.05M	-41.44M	-29.09M	-15.63M	-17.41M
Balance Sheet
Total Assets	43.84M	41.97M	49.22M	30.95M	40.20M	33.66M
Cash, Cash Equivalents and Short-Term Investments	12.93M	9.42M	2.68M	11.49M	20.33M	15.86M
Total Debt	0.00	67.00K	11.67M	867.00K	1.27M	1.47M
Total Liabilities	7.36M	8.50M	24.55M	4.80M	4.30M	5.37M
Stockholders Equity	36.48M	33.47M	24.67M	26.15M	35.91M	28.29M
Cash Flow
Free Cash Flow	-39.09M	-52.57M	-37.70M	-27.69M	-18.58M	-14.74M
Operating Cash Flow	-38.58M	-44.71M	-29.14M	-27.69M	-16.08M	-14.71M
Investing Cash Flow	-3.15M	-8.36M	-8.57M	0.00	-2.50M	-3.26M
Financing Cash Flow	52.87M	59.75M	28.91M	18.85M	23.05M	31.14M

Prostatype Genomics AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Positive. The current price of 0.75 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 0.78, and below the 200-day MA of 0.89, indicating a bullish trend. The MACD of 0.36 indicates Negative momentum. The RSI at 73.62 is Negative, neither overbought nor oversold. The STOCH value of 65.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:PROGEN.

Prostatype Genomics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PROGEN	48 Neutral	kr114.53M	-0.81	-181.36%	―	-67.76%	95.76%
BIOVIC.B	44 Neutral	kr126.96M	-0.81	-72.82%	―	40.91%	57.92%
LARK	43 Neutral	kr43.76M	-0.98	―	8.47%	-94.12%	-25.83%
STABL	42 Neutral	kr13.45M	-1.23	-91.33%	―	―	64.02%
LIDDS	41 Neutral	kr2.43M	-0.42	-132.58%	―	―	86.26%